健康管理人群高脂血症风险预测模型
A prediction model of hyperlipidemia risk based on the health management population

DOI: 10.6040/j.issn.1671-7554.0.2017.402

Keywords: 风险预测模型,队列,健康管理人群,高脂血症,
Longitudinal cohort,Hyperlipidemia,Risk prediction model,Health management population

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Erem C, Hacihasanoglu A, Deger O, et al. Prevalence of dyslipidemia andassociated risk factors among Turkish adults: Trabzon lipid study[J]. Endocrine, 2008, 34(1-3):36-51.
[2]	吴兆苏, 姚崇华, 赵冬, 等. 11省市队列人群心血管疾病前瞻性研究II, 个体危险因素聚集与心血管病发病的关系[J]. 中华心血管病杂志, 2001, 29(4): 246-250. WU Zhaosu, YAO Chonghua, ZHAO Dong, et al. A prospective cohort study on cardiovascular disease incidence in 11 provinces in China. Associations between individual risk factor aggregation and cardiovascular disease incidence[J]. Chin J Cardiol, 2001, 29(4): 246-250.
[3]	Zhao WH, Zhang J, Zhai Y, et al. Blood lipid profile and prevalence of dyslipidemia in Chinese adults[J]. Biomed Environ Sci, 2007, 20(4): 329-335.
[4]	周红,德吉央宗,余光华. 87例中老年高脂血症患病情况调查[J]. 西南民族大学学报, 2011, 37(2): 246-249. ZHOU Hong, DEJIYANGZONG, YU Guanghua. A survey on 87 cases of old hyperlipidermia[J]. Journal of Southwest University for Nationalities, 2011, 37(2): 246-249.
[5]	Martin SS, Michos ED. Mapping hyperlipidemia in young adulthood to coronary risk: importance of cumulative exposure and how to stay young[J]. Circulation, 2015, 131(5): 445-447.
[6]	谢娟, 来则民, 黄国伟, 等. 高脂血症危险因素研究[J]. 疾病控制杂志, 2004, 4(1): 64-66. XIE Juan, LAI Zemin, HUANG Guowei, et al. Study on risk factor of hyperlipidemia[J]. Chin J Dis Control Prev, 2004, 4(1): 64-66.
[7]	Wang SH, Sun ZL, Ruan XZ, et al. Dyslipidaemia among diabetic patients with ischemic stroke in a Chinese hospital[J]. Chin Med J, 2009, 122(21): 2567-2572.
[8]	Ascunce RR, Berger JS, Weintraub HS, et al. The role of statin therapy for primary prevention: what is the evidence?[J]. Curr Atheroscler Rep, 2012, 14(2): 167-174.
[9]	Marschner IC, Colquboun D, Simes RJ, et al. Long-term risk stratification for survisors of acute coronary syndromes. Results from the long-term intervention with pravastatin in ischemic disease(LIPID)study[J]. J Am Coll Cardiol, 2001, 38(1): 56-63.
[10]	Cholesterol Treatment Trialists’ Collaborators. Efficacy and safety of cholesterol-lowing treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins[J]. Lancet, 2005, 366(9493): 1267-1278.
[11]	He J, Gu D, Reynolds K, et al. Serum total and lipprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China[J]. Circulation, 2004, 110(4): 405-411.
[12]	Wu JY, Duan XY, Li L, et al. Dyslipidemia in Shanghai, China[J]. Prev Med, 2010, 51(5): 412-415.
[13]	Lauer MS, Fontanrosa PB. Updated guidelines for cholesterol management[J]. JAMA, 2001, 285(19): 2508-2509.
[14]	Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus and cardiovascular disease: clinical implications[J]. Am J Cardiol, 2008, 102(12A): 5L-9L.
[15]	Hopkins AL, Lamm MG, Funk JL, et al. Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies[J]. Fitoterapia, 2013, 85: 84-94.
[16]	Erem C, Hacihasanoglu A, Deger O, et al. Prevalence of dyslipidemia and associated risk factor among Turkish adults: Trabzon lipid study[J]. Endocr, 2008, 34(1-3): 36-51.
[17]	Li Z, Yang R, Xu G, et al. Serum lipid concentrations and prevalence of dyslipidemia in a large professional population in Beijing[J]. J Clin Chem,2005, 51(1): 144-150.
[18]	赵文华, 张坚, 由悦, 等. 中国18岁及以上人群血脂异常流行特点研究[J]. 中华预防医学杂志, 2005, 39(5): 306-310. ZHAO Wenhua, ZHANG Jian, YOU Yue, et al. Epidemiologic characteristics of dyslipidemia in people aged 18 years and over in China[J]. Chine Pre Med, 2005, 39(5): 306-310.
[19]	Friedman JI, Tang CY, de Haas HJ, et al. Brain imaging changes associated with risk factors for cardiovascular and cerebrovascular disease in asymptomatic patients[J]. JACC Cardiovasc Imaging, 2014, 7(10): 1039-1053.
[20]	中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华循环杂志, 2016, 31(10): 937-953.
[21]	Tietge UJ. Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis[J]. Curr Opin Lipidol, 2014, 25(1): 94-95.
[22]	SU M, FU C, LI S,et al. Prevalence of hyperlipidemia and possible risk factors in rural Chinese adults: cohort study of health population in Yuhuan rural[J].Wei Sheng Yan Jiu, 2013, 42(5): 724-729.
[23]	Navar-Boggan AM, Peterson ED, Dagostino RB, et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease[J]. Circulation, 2015, 131(5): 451-458.
[24]	Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease[J]. Prim Care, 2013, 40(1): 195-211.
[25]	Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, et al. Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy[J]. Rheumatol Int, 2010, 30(8): 1125-1129.
[26]	邵金凤,谭先娥.生活方式干预对血脂异常人群的影响[J]. 护理学杂志, 2006, 21(5): 66-67. SHAO Jinfeng, TAN Xiane. Effect of intervention about the cure of lifestyle in the blood fat abnormity crowd[J]. Journal of Nursing Science, 2006, 21(5): 66-67.
[27]	Chen G, Wang H, Zhang X, et al. Nutraceuticals and functional foods in the management of hyperlipidemia[J]. Crit Rev Food Sci Nutr, 2014, 54(9): 1180-1201.

Full-Text